Plasma Lipid Profiling Increased Cardiometabolic Risks in Acute Myeloid Leukaemia Patients Pre- and Post-chemotherapy

Research output: Contribution to journalArticlepeer-review


Background: Haematological malignancy affects lipid homeostasis representing elevated risks of cardiometabolic diseases. This study investigated the alteration of plasma lipids/lipoproteins and the underlying regulation mechanism. Materials and Methods: Blood samples were collected from acute myeloid leukaemia (AML) patients pre-and post-chemotherapy and matched controls. Triglyceride (TG), total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-c), low-density-lipoprotein cholesterol (LDL-c) and apolipoproteins (apo) were quantified in plasma and lipoprotein-density-gradient fractions. The cardiometabolic risks and lipid loads were assessed. Results: Dyslipidaemia was revealed in 75% of AML patients pre-therapy by reduction of HDL-c and in 85% post-therapy by diverse combined patterns. Compared to the controls, AML patients exhibited increased plasma TG and cardiometabolic risks both pre- and post-therapy. The plasma TC, HDL-c, apoAI, B-100, CIII and J were decreased pre-therapy but were restored post-therapy. The plasma TG concentration was positively correlated with LDL-TG load, whereas plasma TC was positively correlated with HDL-c. Furthermore, the fractionated very-low-density lipoprotein (VLDL)-TG load was lower but LDL-TG load was higher in AML patients than in the controls, suggesting that circulating TG hydrolysis might be impaired from VLDL conversion to LDL. Conclusion: The plasma lipid profiles in AML were aberrant and predicted high cardiometabolic risks, which might need further follow-up attentions.
Translated title of the contribution血液脂質分析顯示急性骨髓性白血病人接受治療後增加心臟代謝疾病風險
Original languageEnglish
Pages (from-to)79-91
Number of pages13
JournalJournal of Biomedical & Laboratory Sciences = 生物醫學暨檢驗科學雜誌
Issue number2
Publication statusPublished - 2022 Jun 30


Dive into the research topics of 'Plasma Lipid Profiling Increased Cardiometabolic Risks in Acute Myeloid Leukaemia Patients Pre- and Post-chemotherapy'. Together they form a unique fingerprint.

Cite this